Related Experiment Videos
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive
1Division of Pediatric Neurosurgery, Children's Hospital Los Angeles, California, USA.
Abstract:
The recently described multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 (MTS1/CDKN2) gene, encoding the cyclin-dependent kinase 4 inhibitor p16, is mutated in a wide variety of tumor cell lines, including gliomas. To investigate the possible role of this gene in the genesis of the central nervous system primitive neuroectodermal tumor (PNET), four established PNET cell lines and 18 PNET surgical specimens were studied for deletions and mutations of the MTS1/CDKN2 gene. One of the four cell lines had homozygous deletion of the gene. No mutation in any of the three MTS1/CDKN2 exons was detected in the other three cell lines by single strand conformational polymorphism analysis. Eighteen surgical PNET specimens were studied for allelic and homozygous deletion at chromosome 9p21, the location of the MTS1/CDKN2 gene. No loss of heterozygosity was noted in 11 of the tumors, and no homozygous loss was noted in any tumor. Single strand conformational polymorphism analysis of the entire coding region of the MTS1/CDKN2 gene revealed no mutation within MTS1/CDKN2 in any tumor. Although deletion of MTS1/CDKN2 may occur in some PNET cell lines, neither deletion nor mutation of the gene is found in tumors before culture. The genesis of the human central nervous system PNET does not involve deletion or mutation of the MTS1/CDKN2 gene.
Insights
The MTS1/CDKN2 gene, important in tumor suppression, is not mutated or deleted in central nervous system primitive neuroectodermal tumors (PNETs). This suggests MTS1/CDKN2 alterations do not drive PNET development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The MTS1/CDKN2 gene encodes the p16 protein, a cyclin-dependent kinase inhibitor.
- MTS1/CDKN2 alterations are observed in various tumor cell lines, including gliomas.
- The role of MTS1/CDKN2 in central nervous system primitive neuroectodermal tumor (PNET) genesis requires investigation.
Purpose of the Study:
- To investigate the potential role of MTS1/CDKN2 gene deletions and mutations in the development of human central nervous system PNETs.
Main Methods:
- Analysis of four established PNET cell lines and 18 PNET surgical specimens.
- Studied deletions and mutations of the MTS1/CDKN2 gene.
- Utilized single-strand conformational polymorphism (SSCP) analysis for mutation detection.
- Examined allelic and homozygous deletion at chromosome 9p21, the gene's location.
Main Results:
- One PNET cell line exhibited homozygous deletion of the MTS1/CDKN2 gene.
- No mutations were detected in the MTS1/CDKN2 exons of the remaining three cell lines.
- No loss of heterozygosity or homozygous loss of MTS1/CDKN2 was found in any of the 18 PNET surgical specimens.
- SSCP analysis revealed no MTS1/CDKN2 mutations in any tumor specimens.
Conclusions:
- While MTS1/CDKN2 deletion may occur in cultured PNET cell lines, it is not present in tumors prior to culture.
- Deletion or mutation of the MTS1/CDKN2 gene is not implicated in the genesis of human central nervous system PNETs.